ISLHD HAEMATOLOGY CLINICAL TRIALS

Illawarra Cancer Care Centre

June 2024

ISLHD CANCER CLINICAL TRIALS UNIT

Illawarra Cancer Care Centre Wollongong Hospital Loftus Street Wollongong NSW 2500

Ph: 02 4253 4384 Fax: 02 4222 5085 Email: ISLHD-CancerClinicalTrials@health. nsw.gov.au

Clinical Trials available through the Illawarra Shoalhaven Local Health District can be found on the ClinTrial Refer App. Scan the QR code below to download ClinTrial Refer.



The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.


Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Multiple Myeloma
- Acute myeloid Leukaemia

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Haematology Trials Clinician, please phone Haematology on 02 4253 4009



ISLHD Haematology Clinical Trials **CURRENTLY OPEN FOR RECRUITMENT**

Scan the QR Code for more information including eligibility criteria

Multiple Myeloma ACT16482: Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM).

CA057-001: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM). **recruitment paused**

MAJESTEC-7: A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy.

MonumenTAL-2: A multi-arm phase 1b study of talguetamab with other anticancer therapies in participants with multiple myeloma.

MonumenTAL-6: A Study Comparing Talguetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide. Bortezomib. and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide.

TCD17710: First-in-human, open-label Phase 1/2 study Dr Parmar to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation an- Carroll-Cross/ tigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light chain amyloidosis (RRLCA).

LTS17704: International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximabbased Therapy Following Completion of a Phase 1, 2, or 3 Parental Study. **Parental study TCD15484**

Dr Parmar Felicity Carroll-Cross/ Cassandra Jory

Dr Parmar Kiara Porter/ Tegan Cutter *Satellite site





Dr Parmar Carla Brown/ **Tegan Cutter**



Dr Parmar Tegan Cutter/ Kiara Porter



Dr Parmar Tegan Cutter/ Carla Brown



Felicitv Cassandra Jory



Dr Parmar Tiffany Koutsouradis/ Amelia Feneck



ISLHD Haematology Clinical Trials **CURRENTLY OPEN FOR RECRUITMENT**

Acute Leukaemia

AMLM22/D2: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Dr Presgrave Carla Brown



For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email <u>ISLHD-HaematologyTrials</u> @health.nsw.gov.au

| Trial Coordinator | Availability | Contact details |
|----------------------------------|--------------|-----------------|
| Danielle Di Pietro (team leader) | Mon-Fri | 02 4255 1415 |
| Tameika Tubaro (CNS2) | Mon-Thurs | 02 4222 5230 |
| Felicity Carroll-Cross | Mon-Fri | 02 4253 4039 |
| Tegan Cutter | Mon-Fri | 02 4253 4173 |
| Kiara Porter | Mon-Fri | 02 4222 5276 |
| Carla Brown | Mon-Wed | 02 4253 4082 |
| Cassandra Jory | Wed-Fri | 02 4222 5553 |
| Tiffany Koutsouradis | Wed-Fri | 02 4253 4933 |
| Jillian Dubose | Tues-Fri | 02 4255 1495 |
| Amelia Feneck | Mon-Wed | 02 4253 4933 |

